Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Désirée Van Der Heijde, Lianne S. Gensler, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Alan Kivitz, Mary Katherine Farmer, Dominique Baeten, Nadine Goldammer, Jason Coarse, Marga Oortgiesen, Maxime Dougados

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Fingerprint

Dive into the research topics of 'Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds